Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis
Gastric Cancer · 2025
DOI: 10.1007/s10120-025-01640-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastric Cancer, 2025. Verfasst von Koji Nagaoka und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Kindai University, Faculty of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka, 589-0014, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Peritoneal Neoplasms, Antigens, Neoplasm, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background
Gastric cancer with peritoneal metastasis is associated with a poor prognosis. Current treatments, including the first-line therapy of combination chemotherapy with nivolumab for advanced recurrent gastric cancer, have shown limited efficacy against peritoneal dissemination. In this study, we evaluated neoantigen (neoAg)-mRNA lipid nanoparticle (LNP) as a potential agent in combination with anti-PD-1 therapy, focusing on its effects on neoAg-specific CD8 + T cell responses and antitumor efficacy in a murine gastric cancer model.
Methods
The mRNA, comprising a tandem minigene encoding three neoAgs identified from the murine gastric cancer YTN16 cell line, was synthesized by in vitro transcription and encapsulated within LNPs. NeoAg-specific CD8 + T cells in the spleens and tumors were assessed by flow cytometry. The antitumor efficacy of the neoAg-mRNA-LNP vaccine, alone or in combination with anti-PD-1 antibody, was evaluated in both subcutaneous and peritoneal metastasis models of YTN16.
Results
The neoAg-mRNA-LNP vaccine induced significantly higher frequencies of neoAg-specific CD8 + T cells than the neoAg-dendritic cell vaccine, confirming its enhanced immunogenicity. NeoAg-mRNA-LNP vaccination led to robust tumor regression, achieving complete eradication in all treated mice, especially when combined with anti-PD-1 therapy. This effect was associated with an increase in neoAg-specific progenitor-exhausted and intermediate-exhausted CD8 + T cells. In a peritoneal metastasis model, neoAg-mRNA-LNP monotherapy prevented peritoneal dissemination when administered prophylactically, and combination therapy with anti-PD-1 effectively suppressed tumor growth in a therapeutic setting.
Conclusions
NeoAg-mRNA-LNP vaccines elicit potent neoAg-specific CD8 + T cell responses and show enhanced antitumor efficacy with anti-PD-1 therapy in gastric cancer with peritoneal metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Kindai University, Faculty of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka, 589-0014, Japan.
- Department of Biofunction Research, Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, 2-3-10 Kanda-Surugadai, Chiyoda-Ku, Tokyo, 101-0062, Japan.
- Clinical Biotechnology Team, Center for Infectious Disease Education and Research (CiDER), The University of Osaka, 1-10 Yamadaoka, Suita, Osaka, 565-0871, Japan.
- Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-Ku, Sendai, 980-8578, Japan.
- Isotope Science Center, The University of Tokyo, 2-11-16 Yayoi, Bunkyo-Ku, Tokyo, 113-0032, Japan.
- Laboratories for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Komaba, Meguro-Ku, Tokyo, 153-8904, Japan.
ORCID-Profile: Kazuhiro Kakimi
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Nagaoka, K., Nakanishi, H., Tanaka, H., Anindita, J., Kawamura, T., Tanaka, T., Yamashita, T., Kuroda, A., Nomura, S., Akita, H., Itaka, K., Kodama, T., & Kakimi, K. (2025). Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis. Gastric Cancer. https://doi.org/10.1007/s10120-025-01640-8
Vancouver
Nagaoka K, Nakanishi H, Tanaka H, Anindita J, Kawamura T, Tanaka T, et al. Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis. Gastric Cancer. 2025. doi:10.1007/s10120-025-01640-8
BibTeX
@article{Nagaoka2025,
author = {Nagaoka, Koji and Nakanishi, Hideyuki and Tanaka, Hiroki and Anindita, Jessica and Kawamura, Takeshi and Tanaka, Toshiya and Yamashita, Takefumi and Kuroda, Akihiro and Nomura, Sachiyo and Akita, Hidetaka and Itaka, Keiji and Kodama, Tatsuhiko and Kakimi, Kazuhiro},
title = {Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis},
journal = {Gastric Cancer},
year = {2025},
doi = {10.1007/s10120-025-01640-8}
}
EUVIMED